Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -2.74 Decreased by -12.82% | -2.17 Decreased by -26.27% |
| May 12, 25 | -2.49 Decreased by -2.05% | -2.62 Increased by +5.01% |
| Mar 24, 25 | -2.26 Increased by +91.19% | -2.51 Increased by +10.06% |
| Nov 1, 24 | -2.26 Increased by +85.42% | -2.61 Increased by +13.41% |
| Aug 8, 24 | -2.43 Decreased by -709.57% | -2.39 Decreased by -1.62% |
| May 14, 24 | -2.44 Decreased by -343.64% | -2.51 Increased by +2.79% |
| Mar 26, 24 | -25.65 Decreased by -5.13 K% | -2.36 Decreased by -986.86% |
| Nov 2, 23 | -15.50 Decreased by -2.72 K% | -17.73 Increased by +12.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 1.46 M Increased by +N/A% | -25.77 M Decreased by -18.07% | Decreased by -1.77 K% Decreased by N/A% |
| Mar 31, 25 | 2.55 M Increased by +N/A% | -23.39 M Decreased by -19.58% | Decreased by -917.14% Decreased by N/A% |
| Dec 31, 24 | 2.27 M Increased by +N/A% | -21.20 M Increased by +45.95% | Decreased by -933.47% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.00 M Decreased by -80.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.83 M Decreased by -102.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -19.56 M Decreased by -0.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -39.22 M Decreased by -125.89% | Decreased by N/A% - |
| Sep 30, 23 | 0.00 Decreased by N/A% | -11.61 M Increased by +40.58% | Decreased by N/A% - |